Bicara Therapeutics, Inc. (BCAX)
22.02
-0.62
(-2.74%)
USD |
NASDAQ |
Sep 21, 16:00
22.02
0.00 (0.00%)
After-Hours: 20:00
Bicara Therapeutics Total Assets (Quarterly) : 512.24M for June 30, 2026
Total Assets (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 512.24M |
| March 31, 2026 | 553.60M |
| December 31, 2025 | 529.30M |
| September 30, 2025 | 424.69M |
| June 30, 2025 | 453.59M |
| March 31, 2025 | 478.08M |
| Date | Value |
|---|---|
| December 31, 2024 | 569.20M |
| September 30, 2024 | 524.17M |
| June 30, 2024 | 208.78M |
| March 31, 2024 | |
| December 31, 2023 | 233.98M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 2.112B |
| Oncolytics Biotech, Inc. | 7.671M |
| Sangamo Therapeutics, Inc. | 59.96M |
| Sarepta Therapeutics, Inc. | 3.189B |
| Anixa Biosciences, Inc. | 15.07M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 43.48M |
| Shareholders Equity (Quarterly) | 468.77M |
| Debt to Equity Ratio | 0.0025 |
| Current Ratio | 11.59 |
| Net Debt Paydown Yield | -0.01% |